SCHEMBL14903406

SCHEMBL14903406

CC(=O)[C@H](Cc1ccccc1)NC(=O)C[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CCCN1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CTRB1 P17538 1/20 0.47
▸ REN P00797 3/20 0.46
▸ OPRM1 P35372 1/20 0.45
▸ OPRD1 P41143 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ DPP4 P27487 1/20 0.45
▸ ACE P12821 1/20 0.43
▸ NMUR2 Q9GZQ4 1/20 0.43
▸ NMUR1 Q9HB89 1/20 0.43
▸ CTSC P53634 1/20 0.43
▸ TACR1 P25103 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14906464 0.93 CTRB1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL6876603 0.93 CTRB1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL6880524 0.93 CTRB1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL14906471 0.93 CTRB1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL6876472 0.93 CTRB1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL6878588 0.93 CTRB1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL14906683 0.91 ALDH1A1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL14906688 0.91 ALDH1A1 (0.48) CTRB1RENDPP4ACECTSC
SCHEMBL14903296 0.90 REN (0.45) CTRB1RENDPP4
SCHEMBL14903439 0.90 REN (0.45) CTRB1RENDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10238713-B2 Cyclic tetrapeptides and therapeutic applications thereof LODZ UNIVERSITY OF TECHNOLOGY (PL) 2019-03-26 — — US disclosed
US-20170157204-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF LODZ UNIVERSITY OF TECHNOLOGY (PL) 2017-06-08 — — US disclosed
US-20170157204-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF LODZ UNIVERSITY OF TECHNOLOGY (PL) 2017-06-08 — — US disclosed
US-9382292-B2 Cyclic tetrapeptides and therapeutic applications thereof PEPTADERM SP. Z O.O. (PL) 2016-07-05 — — US disclosed
US-9382292-B2 Cyclic tetrapeptides and therapeutic applications thereof PEPTADERM SP. Z O.O. (PL) 2016-07-05 — — US disclosed
US-20130224232-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF LODZ UNIVERSITY OF TECHNOLOGY (PL) 2013-08-29 — — US disclosed
US-20130224232-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF LODZ UNIVERSITY OF TECHNOLOGY (PL) 2013-08-29 — — US disclosed
US-20130108655-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PEPTADERM SP. Z O.O. (PL) 2013-05-02 — — US disclosed
US-20130108655-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PEPTADERM SP. Z O.O. (PL) 2013-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170157204-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PNISR, APLNR, VIP CTRB1 1251/4885REN 119/4885OPRM1 1275/4885
US-20130108655-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PNISR, APLNR, VIP CTRB1 1251/4885REN 119/4885OPRM1 1275/4885
US-10238713-B2 Cyclic tetrapeptides and therapeutic applications thereof PNISR, APLNR, VIP CTRB1 1251/4885REN 119/4885OPRM1 1275/4885
US-20130224232-A1 CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF PNISR, VIP, APLNR CTRB1 956/4885REN 85/4885OPRM1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback